These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35656590)

  • 1. MicroRNA inhibition using antimiRs in acute human brain tissue sections.
    Morris G; Langa E; Fearon C; Conboy K; Lau E-How K; Sanz-Rodriguez A; O'Brien DF; Sweeney K; Lacey A; Delanty N; Beausang A; Brett FM; Cryan JB; Cunningham MO; Henshall DC
    Epilepsia; 2022 Aug; 63(8):e92-e99. PubMed ID: 35656590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle-complexed antimiRs for inhibiting tumor growth and metastasis in prostate carcinoma and melanoma.
    Kunz M; Brandl M; Bhattacharya A; Nobereit-Siegel L; Ewe A; Weirauch U; Hering D; Reinert A; Kalwa H; Guzman J; Weigelt K; Wach S; Taubert H; Aigner A
    J Nanobiotechnology; 2020 Nov; 18(1):173. PubMed ID: 33228711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceleration of Diabetic Wound Healing with PHD2- and miR-210-Targeting Oligonucleotides.
    Dallas A; Trotsyuk A; Ilves H; Bonham CA; Rodrigues M; Engel K; Barrera JA; Kosaric N; Stern-Buchbinder ZA; White A; Mandell KJ; Hammond PT; Mansbridge J; Jayasena S; Gurtner GC; Johnston BH
    Tissue Eng Part A; 2019 Jan; 25(1-2):44-54. PubMed ID: 29644938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of microRNA function by antimiR oligonucleotides.
    Stenvang J; Petri A; Lindow M; Obad S; Kauppinen S
    Silence; 2012 Jan; 3(1):1. PubMed ID: 22230293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LNA-mediated microRNA silencing in non-human primates.
    Elmén J; Lindow M; Schütz S; Lawrence M; Petri A; Obad S; Lindholm M; Hedtjärn M; Hansen HF; Berger U; Gullans S; Kearney P; Sarnow P; Straarup EM; Kauppinen S
    Nature; 2008 Apr; 452(7189):896-9. PubMed ID: 18368051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored Nanoparticle Codelivery of antimiR-21 and antimiR-10b Augments Glioblastoma Cell Kill by Temozolomide: Toward a "Personalized" Anti-microRNA Therapy.
    Ananta JS; Paulmurugan R; Massoud TF
    Mol Pharm; 2016 Sep; 13(9):3164-75. PubMed ID: 27508339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid nanoparticle delivery of a microRNA-145 inhibitor improves experimental pulmonary hypertension.
    McLendon JM; Joshi SR; Sparks J; Matar M; Fewell JG; Abe K; Oka M; McMurtry IF; Gerthoffer WT
    J Control Release; 2015 Jul; 210():67-75. PubMed ID: 25979327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound and Microbubble-targeted Delivery of a microRNA Inhibitor to the Heart Suppresses Cardiac Hypertrophy and Preserves Cardiac Function.
    Kopechek JA; McTiernan CF; Chen X; Zhu J; Mburu M; Feroze R; Whitehurst DA; Lavery L; Cyriac J; Villanueva FS
    Theranostics; 2019; 9(23):7088-7098. PubMed ID: 31660088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly efficient silencing of microRNA by heteroduplex oligonucleotides.
    Yoshioka K; Kunieda T; Asami Y; Guo H; Miyata H; Yoshida-Tanaka K; Sujino Y; Piao W; Kuwahara H; Nishina K; Hara RI; Nagata T; Wada T; Obika S; Yokota T
    Nucleic Acids Res; 2019 Aug; 47(14):7321-7332. PubMed ID: 31214713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?
    Biglino G; Caputo M; Rajakaruna C; Angelini G; van Rooij E; Emanueli C
    Pharmacol Ther; 2017 Feb; 170():192-204. PubMed ID: 27902930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of different chemically modified inhibitors of miR-199b in vivo.
    Duygu B; Juni R; Ottaviani L; Bitsch N; Wit JBM; de Windt LJ; da Costa Martins PA
    Biochem Pharmacol; 2019 Jan; 159():106-115. PubMed ID: 30452907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting microRNA-134 for seizure control and disease modification in epilepsy.
    Morris G; Reschke CR; Henshall DC
    EBioMedicine; 2019 Jul; 45():646-654. PubMed ID: 31300345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases.
    Ooi JYY; Bernardo BC; Singla S; Patterson NL; Lin RCY; McMullen JR
    RNA Biol; 2017 May; 14(5):500-513. PubMed ID: 27124358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function.
    Bernardo BC; Gao XM; Winbanks CE; Boey EJ; Tham YK; Kiriazis H; Gregorevic P; Obad S; Kauppinen S; Du XJ; Lin RC; McMullen JR
    Proc Natl Acad Sci U S A; 2012 Oct; 109(43):17615-20. PubMed ID: 23047694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and challenges for microRNA-targeting therapeutics for epilepsy.
    Morris G; O'Brien D; Henshall DC
    Trends Pharmacol Sci; 2021 Jul; 42(7):605-616. PubMed ID: 33992468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective silencing of miR-126 after ischemic stroke by means of intravenous α-tocopherol-conjugated heteroduplex oligonucleotide in mice.
    Suzuki M; Ishibashi S; Iwasawa E; Oguma T; Saito Y; Li F; Otsu S; Ichinose K; Yoshioka K; Nagata T; Yokota T
    Sci Rep; 2021 Jul; 11(1):14237. PubMed ID: 34244578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for natural antisense transcript-mediated inhibition of microRNA function.
    Faghihi MA; Zhang M; Huang J; Modarresi F; Van der Brug MP; Nalls MA; Cookson MR; St-Laurent G; Wahlestedt C
    Genome Biol; 2010; 11(5):R56. PubMed ID: 20507594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy.
    Venø MT; Reschke CR; Morris G; Connolly NMC; Su J; Yan Y; Engel T; Jimenez-Mateos EM; Harder LM; Pultz D; Haunsberger SJ; Pal A; Heller JP; Campbell A; Langa E; Brennan GP; Conboy K; Richardson A; Norwood BA; Costard LS; Neubert V; Del Gallo F; Salvetti B; Vangoor VR; Sanz-Rodriguez A; Muilu J; Fabene PF; Pasterkamp RJ; Prehn JHM; Schorge S; Andersen JS; Rosenow F; Bauer S; Kjems J; Henshall DC
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15977-15988. PubMed ID: 32581127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canonical and non-canonical barriers facing antimiR cancer therapeutics.
    Cheng CJ; Saltzman WM; Slack FJ
    Curr Med Chem; 2013; 20(29):3582-93. PubMed ID: 23745563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.